CN105495617A - 一种减肥及辅助降血脂的保健食品及其制备方法 - Google Patents
一种减肥及辅助降血脂的保健食品及其制备方法 Download PDFInfo
- Publication number
- CN105495617A CN105495617A CN201510953849.5A CN201510953849A CN105495617A CN 105495617 A CN105495617 A CN 105495617A CN 201510953849 A CN201510953849 A CN 201510953849A CN 105495617 A CN105495617 A CN 105495617A
- Authority
- CN
- China
- Prior art keywords
- oil
- preparation
- fat
- health
- evening primrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 150000002632 lipids Chemical class 0.000 title abstract description 11
- 239000008280 blood Substances 0.000 title abstract description 9
- 210000004369 blood Anatomy 0.000 title abstract description 9
- 235000013305 food Nutrition 0.000 title abstract 4
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 16
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 16
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 16
- 239000007901 soft capsule Substances 0.000 claims abstract description 16
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 14
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 13
- 235000013871 bee wax Nutrition 0.000 claims abstract description 10
- 239000003921 oil Substances 0.000 claims description 19
- 235000008524 evening primrose extract Nutrition 0.000 claims description 17
- 229940089020 evening primrose oil Drugs 0.000 claims description 17
- 239000010475 evening primrose oil Substances 0.000 claims description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 235000013402 health food Nutrition 0.000 claims description 14
- 239000003292 glue Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 9
- 230000002402 anti-lipaemic effect Effects 0.000 claims description 9
- 239000012166 beeswax Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 229920000159 gelatin Polymers 0.000 claims description 9
- 239000008273 gelatin Substances 0.000 claims description 9
- 235000019322 gelatine Nutrition 0.000 claims description 9
- 235000011852 gelatine desserts Nutrition 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 6
- 238000004040 coloring Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000009413 insulation Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000084 colloidal system Substances 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 239000010779 crude oil Substances 0.000 claims description 3
- 239000007887 hard shell capsule Substances 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000004062 sedimentation Methods 0.000 claims description 3
- -1 stir 30 minutes Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000003754 machining Methods 0.000 claims 1
- 241000219925 Oenothera Species 0.000 abstract description 4
- 235000004496 Oenothera biennis Nutrition 0.000 abstract description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 13
- 235000019197 fats Nutrition 0.000 description 8
- 210000004003 subcutaneous fat Anatomy 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 241001247821 Ziziphus Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 210000000852 deltoid muscle Anatomy 0.000 description 4
- 210000003692 ilium Anatomy 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- WUYQEGNOQLRQAQ-CQSZACIVSA-N (+)-pronuciferine Chemical compound C([C@H]1N(C)CCC=2C=C(C(=C3C=21)OC)OC)C13C=CC(=O)C=C1 WUYQEGNOQLRQAQ-CQSZACIVSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- BHLYRWXGMIUIHG-HNNXBMFYSA-N (S)-reticuline Chemical compound C1=C(O)C(OC)=CC=C1C[C@H]1C2=CC(O)=C(OC)C=C2CCN1C BHLYRWXGMIUIHG-HNNXBMFYSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
- JBGSWIBJAGBGOP-UHFFFAOYSA-N Dehydronuciferine Chemical compound C1=CC=C2C3=C(OC)C(OC)=CC(CCN4C)=C3C4=CC2=C1 JBGSWIBJAGBGOP-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 2
- 240000004980 Rheum officinale Species 0.000 description 2
- 235000008081 Rheum officinale Nutrition 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- RUPUUZZJJXCDHS-UHFFFAOYSA-N (+)-orientaline Natural products C1=C(O)C(OC)=CC(CC2C3=CC(O)=C(OC)C=C3CCN2C)=C1 RUPUUZZJJXCDHS-UHFFFAOYSA-N 0.000 description 1
- WUYQEGNOQLRQAQ-UHFFFAOYSA-N (+)-pronuciferine Natural products C1=2C3=C(OC)C(OC)=CC=2CCN(C)C1CC13C=CC(=O)C=C1 WUYQEGNOQLRQAQ-UHFFFAOYSA-N 0.000 description 1
- FFDULTAFAQRACT-NYYYOYJKSA-N (-)-syringaresinol O,O'-bis(beta-D-glucoside) Chemical compound COC1=CC([C@H]2[C@H]3[C@H]([C@@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C(OC)C=3)CO2)=CC(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FFDULTAFAQRACT-NYYYOYJKSA-N 0.000 description 1
- QQKAHDMMPBQDAC-CQSZACIVSA-N (6ar)-1,2-dimethoxy-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1NCC3 QQKAHDMMPBQDAC-CQSZACIVSA-N 0.000 description 1
- BOKVLBSSPUTWLV-INIZCTEOSA-N (S)-N-methylcoclaurine Chemical compound C([C@@H]1N(C)CCC=2C=C(C(=CC=21)O)OC)C1=CC=C(O)C=C1 BOKVLBSSPUTWLV-INIZCTEOSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000062995 Cassia occidentalis Species 0.000 description 1
- 235000001948 Cassia occidentalis Nutrition 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- BOKVLBSSPUTWLV-UHFFFAOYSA-N D-N-Methyl coclaurine Natural products C1=2C=C(O)C(OC)=CC=2CCN(C)C1CC1=CC=C(O)C=C1 BOKVLBSSPUTWLV-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- CBOKHFLBNZMMAA-UHFFFAOYSA-N Emodin anthrone Natural products OC1=CC(O)=CC2=CC3=CC(C)=CC(O)=C3C(O)=C21 CBOKHFLBNZMMAA-UHFFFAOYSA-N 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- QQKAHDMMPBQDAC-UHFFFAOYSA-N N-Nornuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1NCC3 QQKAHDMMPBQDAC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241000245063 Primula Species 0.000 description 1
- 235000016311 Primula vulgaris Nutrition 0.000 description 1
- JCTYWRARKVGOBK-CQSZACIVSA-N Remerin Chemical compound C12=C3C4=CC=CC=C4C[C@H]1N(C)CCC2=CC1=C3OCO1 JCTYWRARKVGOBK-CQSZACIVSA-N 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- JCTYWRARKVGOBK-UHFFFAOYSA-N Roemerine Natural products C12=C3C4=CC=CC=C4CC1N(C)CCC2=CC1=C3OCO1 JCTYWRARKVGOBK-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- LAJSXCAVRQXZIO-UHFFFAOYSA-N emodin anthrone Chemical compound C1=C(O)C=C2CC3=CC(C)=CC(O)=C3C(=O)C2=C1O LAJSXCAVRQXZIO-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- USOSNFWVEWONDB-UHFFFAOYSA-N liriodendrin Natural products COc1cc(cc(OC)c1OC2OC(CO)C(O)C(O)C2O)C3OC(C)(C)C4C(OC(C)(C)C34)c5cc(OC)c(OC6OC(CO)C(O)C(O)C6O)c(OC)c5 USOSNFWVEWONDB-UHFFFAOYSA-N 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 229930001545 pronuciferine Natural products 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- BNUZUOWRDKPBQR-UHFFFAOYSA-N reticuline Natural products CN1CCC2=CC(OC)=CC=C2C1CC1=CC=C(OC)C(O)=C1 BNUZUOWRDKPBQR-UHFFFAOYSA-N 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种减肥及辅助降血脂的保健食品及其制备方法。所述保健食品是由以下重量配比的原料制成的软胶囊制剂:决明子750-1100g,荷叶750-1100g,月见草油230-320g,辅料:蜂蜡8-15g。本发明具有减肥、降血脂、易服用、无毒副作用等特点。
Description
技术领域
本发明涉及保健品领域,具体涉及一种具有保健功能的减肥及辅助降血脂的保健食品及其制备方法,特别是指一种以中草药为原料制成的制剂及其制备方法。
背景技术
近年来,随着我国城乡居民生活的不断改善和提高,随之也出现了由于膳食营养的不尽合理等诸多因素造成的肥胖、高血脂的身体异常症状,而且此类人群还在不断增长扩大。目前市面上也有许多针对肥胖者减肥的保健食品和药品,但大多数产品都是通过服用后抑制服用者的食欲,减少进食量来达到减肥的目的,不能从根本上起到减肥降血脂的作用,而且副作用比较大,造成服用者因食欲低下出现精神状态不佳,精力下降,影响正常的工作和生活质量。
本发明是针对肥胖伴高血脂患者进行科学配伍后制成的。其中,荷叶自古以来就是减肥的佳品,早在明代就有医术记载:“荷叶服之,令人受之”之说,而且以其天然植物无副作用、见效快而颇负胜名。荷叶是“药食两用”的植物,荷叶中富含多种生物碱,如荷叶碱、N-去甲荷叶碱、O-去甲荷叶碱、牛心果碱、斑点亚洲罂粟碱(罗默碱)、亚美尼亚罂粟碱、N-甲基衡州乌药碱、前荷叶碱、鹅掌楸碱、去氢荷叶碱等。研究表明荷叶中的生物碱具有降脂减肥、抗氧化、抑菌、抗病毒等作用。荷叶中还含有黄酮类物质,是大多数痒自由基的清除剂,可以提高SOD(超氧化物歧化酶)的活力,减少MDA(脂质过氧化物丙二醛)及OX-LDL(氧化低密度脂蛋白)的生成,它可以增加冠脉流量,对实验性心肌梗塞有对抗作用;对急性心肌缺血有保护作用;对治疗冠心病、高血压等有显著效果;对降低舒张压,防治心律失常、心血管病等也起重要作用。决明子:又名草决明,味甘苦咸,性微寒,归肝,大肠经,功可清热明目,润肠通便。《神农本草经》说它能“治青盲、目涩、白膜、眼赤痛”等各种眼病,又说它能够使人“轻身”既减轻体重,实际上是指它能够降脂减肥。决明子除含糖类、蛋白质、脂肪外,还含甾体化合物,大黄酚、大黄素等,还有人体必需的微量元素铁、锌、锰、铜、镍、钴、钼等。所含大黄素、大黄酚对人体有平喘、利胆、保肝、降压功效,并有一定抗菌、消炎作用。其中大黄葡萄糖甙、大黄素蒽酮、大黄甲醚,具有降低血清胆固醇和强心作用。现代临床除了将决明子用来治疗白内障、视网膜炎、视神经萎缩、青光眼、结膜炎等眼科疾患之外,又用它来降血脂、降血压和防治动脉硬化等症,用决明子治疗高脂血症疗效满意。月见草油:月见草又被称为晚樱草,主要生长在北美洲东部的向阳处干燥沙地,因它在傍晚见月开花且天亮之后凋谢,故名为月见草。最早是由印第安人发现并使用,数百年来成为维护身体的传统草药之一。目前在我国新疆伊犁地区月见草已经大面积的人工种植成功。月见草油是本世纪发现的重要的营养物质,种子含油20~30%,油中70%为亚油酸,8%~9%为人体必需的γ-亚麻酸。月见草油可治疗多种疾病,调节血液中类脂物质,对高胆固醇、高血脂引起的冠状动脉梗塞、粥样硬化及脑血栓等症有显著疗效,还可治疗多种肥胖症、硬化症、糖尿病、风湿性关节炎和精神分裂症等,在实验室内还发现它有抑制癌症细胞生长的作用。。临床上利用月见草油能防心血管柱塞、降低胆固醇这一特性,用于防止心血管疾病。月见草油中的GLA成分所合成出来的前列腺素,可以刺激棕色脂肪组织,由粒腺体产生能量消耗降低脂肪堆积。其主要功效成分为亚油酸,每100g软胶囊内容物中含亚油酸不少于总脂肪酸的65%。
发明内容
本发明的目的是提供一种用于对肥胖症有保健作用并辅助降血脂的保健食品,且易服用、无毒副作用。
本发明的另一个目的是提供一种制备工艺先进易行、有效成分保留全的减肥辅助降血脂的保健食品的制备方法。
本发明的目的是这样实现的:一种减肥及辅助降血脂的保健食品及其制备方法,
它是由以下重量配比的原料制成的软胶囊制剂:决明子750-1100g,荷叶750-1100g,月见草油230-320g,辅料:蜂蜡8-15g。
在本发明保健食品中,各原料的优选重量配比范围是:决明子880-1000g,荷叶880-1000g,月见草油270-300g,辅料:蜂蜡9-12g。
制备方法:①将捡选过的荷叶、决明子置提取罐中,用10倍量80%乙醇浸泡30分钟,然后回流提取两次,每次2小时,过滤,残渣加入10倍量60%乙醇,回流提取2次,2小时,过滤,合并以上所有提取滤液,滤液回收乙醇浓缩至相对密度1.10~1.30时,减压并在60℃,0.08-0.01MPa的压力下干燥约12~15小时,干燥完毕后粉碎,过120目筛,提取率不得低于8%;②将精选月见籽放入榨油机中,开启榨油机进行榨油,榨油机所出毛油,过滤,滤除杂质,制得精制油;将精制油10~15℃保温自然沉淀24小时,然后过滤,得月见草油备用;③将月见草油置配料罐中,加热,投入蜂蜡搅拌使完全溶解,停止加热,搅拌均匀,投入提取物粉末,搅拌30分钟,制成物料液,经胶体磨加工后,降至室温,备用;将③制得的物料液进行常规后加工处理后可以制成软胶囊、口服液、硬胶囊或片剂等剂型;④软胶囊所用胶皮的制备:明胶15kg,水15kg,甘油4.8kg,焦糖色0.45kg;⑤根据④准确称取原料,再将水加入化胶罐,加入焦糖色溶解,加入甘油搅拌均匀后加热至70℃,加入明胶,继续搅拌至明胶溶解;打开真空泵,抽真空30分钟,停止搅拌,化胶结束;将胶液放入保温桶内,盖好盖子;将保温桶电源插头插入专用温控插座上,胶液60℃保温静置备用;⑥用泵将保温静置好的胶液压出,经展布箱、轮鼓后拉成可压制胶囊的胶皮;⑦将③制成的原料液经注射泵、注射器注射进布满胶皮的压模,挤紧的压模由于外力的作用将包满料液的胶囊切下,即得1000粒软胶囊,其中内容物0.45g/粒。
测试结果及分析:
1.最大摄氧量及主要营养素摄入量的变化
由表1可见,实验前后受试者的最大摄氧量及主要营养摄入量未见明显变化。
2.功效性观察指标
1)体重、体内脂肪总重及脂肪百分率测定
注:*与试食前比较P<0.05,#与对照组比较P<0.05。
试验前,对照组和试食组体重、体脂总量、体脂百分率水平比较,P值均大于0.05,提示两组之间具有可比性。试验后试食组受试者较试验前体重平均下降1.65kg,体脂总量平均下降1.44kg,体脂百分率平均下降1.25%。试验后体重未见明显改变(P<0.05)。试验后试食组受试者体脂总重及体脂百分率与对照组及自身试验前比较差异有显著性(P<0.05)。
2)皮下脂肪厚度测量
注:*与试食前比较P<0.05,#与对照组比较P<0.05。
试验后试食组受试者较试验前皮下脂肪厚度下降,其中三角肌处减少0.53mm,肩胛下处减少0.73mm,脐旁处减少1.05mm,髂棘出减少1.02mm,与试验前比较差异有显著性(P<0.05)。试验后试食组受试者皮下脂肪厚度(肩胛下处,脐旁处及髂棘处)与对照组比较差异有显著性(P<0.05)。三角肌处皮下脂肪厚度与对照组试验后比较无显著性差异(P>0.05)。
3)围径测量结果
注:*与试食前比较P<0.05,#与对照组比较P<0.05。
试验后试食组受试者较试验前腰围减少1.27cm,臀围减少2.24cm。试验后试食组受试者臀围与对照组及自身试验前比较差异有显著性(P<0.05),试验后试食组受试者腰围与对照组及自身试验前比较无显著性差异(P>0.05)。
3.分析
受试者连续食用该具有保健功能的减肥及辅助降血脂的保健食品软胶囊45天,试食组体重平均下降1.65kg,体脂总重平均下降1.44kg,体脂百分率平均下降1.25%;皮下脂肪厚度均下降,其中三角肌处减少0.53mm,肩胛下处减少0.73mm,脐旁处减少1.05mm,髂棘处减少1.02mm;腰围减少1.27cm,臀围减少2.24cm。试食组试验后体脂总重、体脂百分率、皮下脂肪厚度(肩胛下处、脐旁处、髂棘处)及臀围与对照组试验后及自身试验前比较均有显著性差异(P<0.05)。三角肌处皮下脂肪厚度与自身试验前比较有显著性差异(P<0.05),与对照组试验后比较无显著性差异(P>0.05)。试食组试验后体重、腰围指标无显著变化(P>0.05)。试验前后试食组与对照组受试者各项安全性观察指标均未见明显异常改变,试食期间未见明显不良反应。受试对象运动耐力及食欲未见下降。根据《保健食品检验与评价技术规范》(2003年版)评价标准,说明该软胶囊对人体具有减肥并降血脂的保健作用。
具体实施方式
下面结合实施例说明发明的实施方式。
实施例
由下述重量配比的原料制成的软胶囊制剂:决明子750-1100g,荷叶750-1100g,月见草油230-320g,辅料:蜂蜡8-15g。各原料的优选重量配比范围是:决明子880-1000g,荷叶880-1000g,月见草油270-300g,辅料:蜂蜡9-12g。
采用上述配方实施生产工艺如下。
第一步:将捡选过的荷叶、决明子置提取罐中,用10倍量80%乙醇浸泡30分钟,然后回流提取两次,每次2小时,过滤,残渣加入10倍量60%乙醇,回流提取2次,2小时,过滤,合并以上所有提取滤液,滤液回收乙醇浓缩至相对密度1.10~1.30时,减压并在60℃,0.08-0.01MPa的压力下干燥约12~15小时,干燥完毕后粉碎,过120目筛,提取率不得低于8%。
第二步:将精选月见籽放入榨油机中,开启榨油机进行榨油,榨油机所出毛油,过滤,滤除杂质,制得精制油;将精制油10~15℃保温自然沉淀24小时,然后过滤,得月见草油备用。
第三步:将月见草油置配料罐中,加热,投入蜂蜡搅拌使完全溶解,停止加热,搅拌均匀,投入提取物粉末,搅拌30分钟,制成物料液,经胶体磨加工后,降至室温,备用。将制得的物料液进行常规后加工处理后可以制成软胶囊、口服液、硬胶囊或片剂等剂型。
第四步:软胶囊所用胶皮的制备:明胶15kg,水15kg,甘油4.8kg,焦糖色0.45kg。
第五步:根据第四部准确称取原料,再将水加入化胶罐,加入焦糖色溶解,加入甘油搅拌均匀后加热至70℃,加入明胶,继续搅拌至明胶溶解。打开真空泵,抽真空30分钟,停止搅拌,化胶结束。将胶液放入保温桶内,盖好盖子。将保温桶电源插头插入专用温控插座上,胶液60℃保温静置备用。
第六步:用泵将保温静置好的胶液压出,经展布箱、轮鼓后拉成可压制胶囊的胶皮。
第七步:将第三部制成的原料液经注射泵、注射器注射进布满胶皮的压模,挤紧的压模由于外力的作用将包满料液的胶囊切下,即得1000粒软胶囊,其中内容物0.45g/粒。
Claims (3)
1.一种减肥及辅助降血脂的保健食品及其制备方法,其特征在于:所述保健食品是由以下重量配比的原料制成的软胶囊制剂:决明子750-1100g,荷叶750-1100g,月见草油230-320g,辅料:蜂蜡8-15g。
2.根据权利要求1所述的具有保健功能的减肥及辅助降血脂的保健食品,其特征在于,所述保健食品中各原料的重量配比是:决明子880-1000g,荷叶880-1000g,月见草油270-300g,辅料:蜂蜡9-12g。
3.根据权利要求1和2所述的具有保健功能的减肥及辅助降血脂的保健食品的制备方法,其特征在于,包括如下步骤:
①将捡选过的荷叶、决明子置提取罐中,用10倍量80%乙醇浸泡30分钟,然后回流提取两次,每次2小时,过滤,残渣加入10倍量60%乙醇,回流提取2次,2小时,过滤,合并以上所有提取滤液,滤液回收乙醇浓缩至相对密度1.10~1.30时,减压并在60℃,0.08-0.01Mpa的压力下干燥约12~15小时,干燥完毕后粉碎,过120目筛,提取率不得低于8%;
②将精选月见籽放入榨油机中,开启榨油机进行榨油,榨油机所出毛油,过滤,滤除杂质,制得精制油;将精制油10~15℃保温自然沉淀24小时,然后过滤,得月见草油备用;
③将月见草油置配料罐中,加热,投入蜂蜡搅拌使完全溶解,停止加热,搅拌均匀,投入提取物粉末,搅拌30分钟,制成物料液,经胶体磨加工后,降至室温,备用;将③制得的物料液进行常规加工处理后可以制成软胶囊、硬胶囊、片剂或口服液等剂型;
④软胶囊所用胶皮的制备:明胶15kg,水15kg,甘油4.8kg,焦糖色0.45kg;
⑤根据④准确称取原料,再将水加入化胶罐,加入焦糖色溶解,加入甘油搅拌均匀后加热至70℃,加入明胶,继续搅拌至明胶溶解;打开真空泵,抽真空30分钟,停止搅拌,化胶结束;将胶液放入保温桶内,盖好盖子;将保温桶电源插头插入专用温控插座上,胶液60℃保温静置备用;
⑥用泵将保温静置好的胶液压出,经展布箱、轮鼓后拉成可压制胶囊的胶皮;
⑦将③制成的原料液经注射泵、注射器注射进布满胶皮的压模,挤紧的压模由于外力的作用将包满料液的胶囊切下,即得软胶囊。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510953849.5A CN105495617A (zh) | 2015-12-18 | 2015-12-18 | 一种减肥及辅助降血脂的保健食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510953849.5A CN105495617A (zh) | 2015-12-18 | 2015-12-18 | 一种减肥及辅助降血脂的保健食品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105495617A true CN105495617A (zh) | 2016-04-20 |
Family
ID=55704224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510953849.5A Pending CN105495617A (zh) | 2015-12-18 | 2015-12-18 | 一种减肥及辅助降血脂的保健食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105495617A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1660287A (zh) * | 2004-12-08 | 2005-08-31 | 郭来旺 | 降脂胶囊及其制造方法 |
CN101284027A (zh) * | 2008-06-10 | 2008-10-15 | 云南中研万通生物科技有限公司 | 一种降血脂软胶囊的制备方法 |
CN102114207A (zh) * | 2010-12-31 | 2011-07-06 | 王钢柱 | 一种具有治疗高血脂功能的丸剂及其制备方法 |
CN103202926A (zh) * | 2013-03-26 | 2013-07-17 | 威海康博尔生物药业有限公司 | 一种用于防治心脑血管疾病、延缓衰老的软胶囊 |
CN104523829A (zh) * | 2014-12-18 | 2015-04-22 | 威海百合生物技术股份有限公司 | 一种蜂胶丹参保健食品 |
CN104887766A (zh) * | 2015-05-27 | 2015-09-09 | 胡怀强 | 一种治疗动脉粥样硬化的中药复方胶囊及制备方法 |
-
2015
- 2015-12-18 CN CN201510953849.5A patent/CN105495617A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1660287A (zh) * | 2004-12-08 | 2005-08-31 | 郭来旺 | 降脂胶囊及其制造方法 |
CN101284027A (zh) * | 2008-06-10 | 2008-10-15 | 云南中研万通生物科技有限公司 | 一种降血脂软胶囊的制备方法 |
CN102114207A (zh) * | 2010-12-31 | 2011-07-06 | 王钢柱 | 一种具有治疗高血脂功能的丸剂及其制备方法 |
CN103202926A (zh) * | 2013-03-26 | 2013-07-17 | 威海康博尔生物药业有限公司 | 一种用于防治心脑血管疾病、延缓衰老的软胶囊 |
CN104523829A (zh) * | 2014-12-18 | 2015-04-22 | 威海百合生物技术股份有限公司 | 一种蜂胶丹参保健食品 |
CN104887766A (zh) * | 2015-05-27 | 2015-09-09 | 胡怀强 | 一种治疗动脉粥样硬化的中药复方胶囊及制备方法 |
Non-Patent Citations (1)
Title |
---|
周月婵等: "月见草油为主要原料的软胶囊辅助降血脂减肥动物实验", 《中国热带医学》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130099403A1 (en) | Semen cassiae soft capsule for reducing fat and losing weight and preparation method thereof | |
CN101919452B (zh) | 一种复合油保健食品 | |
CN101128211A (zh) | 翠叶芦荟提取物、制备翠叶芦荟提取物的方法和高血糖改善剂 | |
CN104435355A (zh) | 一种叶黄素软胶囊及其制备方法 | |
CN107397208B (zh) | 以鱼鳔胶为主成分的功能食品及其用途 | |
CN101254187A (zh) | 一种治疗代谢综合症的组合物 | |
KR20140143269A (ko) | 홍삼 복합물을 유효성분으로 함유하는 이상지질혈증 예방, 개선 또는 치료를 위한 조성물 | |
KR101517836B1 (ko) | 홍삼 복합물을 유효 성분으로 함유하는 죽상경화증 예방, 개선 또는 치료를 위한 조성물 | |
CN103083429B (zh) | 一种降血脂的中药组合物 | |
KR20180079920A (ko) | 토사자 추출물을 유효성분으로 함유하는 간섬유화 또는 간경화 예방, 개선 또는 치료용 조성물 | |
CN105495617A (zh) | 一种减肥及辅助降血脂的保健食品及其制备方法 | |
CN104256618B (zh) | 一种降血糖的食品、保健品或药物组合物 | |
CN103920135A (zh) | 一种降低尿酸含量的昆布氨基复合片及其制备方法 | |
CN108159296A (zh) | 一种具有清热养阴、降血糖功能的复合多糖及其制备方法与应用 | |
CN108096299B (zh) | 猕猴桃籽活性部位提取分离方法及其应用 | |
CN103478703A (zh) | 一种抗疲劳的保健品及其制备方法 | |
CN106433949A (zh) | 一种低酸价云南松松籽油及其制备方法和应用 | |
CN112843172A (zh) | 提高人体机能和排出有害毒素的中西药组合物及其制备方法 | |
KR100391195B1 (ko) | 맥문동 열수추출을 이용한 다기능음료제조방법 | |
CN104920638A (zh) | 一种保健调和油及其制备方法 | |
CN101804083A (zh) | 松花粉及其提取物在治疗炎症性肠病中的用途及该提取物的制备方法 | |
CN105779103A (zh) | 降三高山茶油及其制备方法 | |
CN104277955A (zh) | 补气养血养生中药酒及制备方法 | |
CN109288058A (zh) | 一种富勒烯增强正常细胞活性的保健品制剂及制备方法 | |
CN108236714B (zh) | 缓解体力疲劳和辅助降血脂的组合物及其软胶囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160420 |
|
RJ01 | Rejection of invention patent application after publication |